Monthly Archives - March 2022

Provider Alert!

Provider Alert! Changes for Client Access to Mosquito Repellent Benefit Begin June 1

Date: March 10, 2022 Attention: Providers Effective Date: June 1, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Beginning May 31, 2022, HHSC will stop using the Texas Medicaid Standing Order for Mosquito Repellent How this impacts providers: Pharmacies must obtain a prescription from a Medicaid-enrolled prescribing...

Provider Alert!

Provider Alert! Abbott Recall of Certain Powdered Formulas: Similac, Alimentum, EleCare, Elecare Jr. and Similac PM 60/40

Date: March 2, 2022  Attention: All Providers Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Regarding system configuration updates, TCHP will apply updates and reprocess impacted claims as soon as possible. However, due to volume, please allow up to sixty (60) business days to complete. Providers...

Provider Alert!

Provider Alert! Prior Authorization Criteria to Change for Omalizumab (Xolair) Effective March 1, 2022

Date: March 3, 2022 Attention: Primary care providers Effective Date: March 01, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Effective on March 1, 2022, prior authorization criteria will change for omalizumab (Xolair) procedure code J2357. Prior authorization requests for clients with chronic idiopathic urticaria...

Provider Alert! COVID-19 Drug Veklury (Remdesivir) is a covered benefit for Medicaid and CHIP clients

Date: March 3, 2022 Attention: Providers Effective Date: January 21, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Beginning January 21, 2022, Veklury (J0248) is a covered benefit for Medicaid and CHIP clients when used in an outpatient setting. How this impacts providers: On January 21,...